REGENXBIO FY2025 EPS Forecast Lowered by Chardan Capital

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for shares of REGENXBIO in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company will post earnings of ($3.03) per share for the year, down from their prior forecast of ($1.39). Chardan Capital currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Chardan Capital also issued estimates for REGENXBIO’s FY2026 earnings at $4.87 EPS.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million.

Several other brokerages have also recently issued reports on RGNX. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a report on Tuesday, March 18th. HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, March 17th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.78.

REGENXBIO Price Performance

RGNX opened at $7.91 on Thursday. The firm has a market cap of $396.18 million, a PE ratio of -1.57 and a beta of 1.35. The stock has a 50-day moving average price of $7.39 and a 200-day moving average price of $8.81. REGENXBIO has a 1 year low of $5.62 and a 1 year high of $22.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the last quarter. FMR LLC raised its position in REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of REGENXBIO during the 4th quarter worth $54,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of REGENXBIO during the 4th quarter worth $79,000. Finally, Laurion Capital Management LP bought a new stake in shares of REGENXBIO during the 4th quarter valued at $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.